Henrik Lawaetz

Scandinavian Life Science Invest ApS (Scandinavian Life Science Invest) is a venture capital firm with offices in Copenhagen and Stockholm. They were founded in 2000. Scandinavian Life Science Invest was created following the merger of the life science team from The Sixth Swedish National Pension Fund, Medicon Valley Capital and Innoventus. Their investor base comprises Scandinavian pension funds, financial institutions, life science firms, and banks.

Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark.

Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis.

Part of BioPheresis Technologies, Inc., Biopheresis GmbH is a German company that provides cancer treatments. The company is based in Heidelberg, Germany.

SANOS Bioscience A/S is a Danish privately owned biotechnology company. Their business is to develop novel treatments for osteoporosis and other skeletal wasting diseases. It was founded in 2003 around patented and proprietary inventions from the Nordic Bioscience Group. This knowledge base includes a profound insight in the biology of skeletal tissue in health, molecular targets, biologicals, and lead compounds. SANOS is focused on the clinical development of SAN-134, an injectable formulation of the intestinal hormone glucagon-like peptide-2, GLP-2 for treatment of diseases with accelerated bone loss, such as osteoporosis. SANOS Bioscience A/S is headquarterd in Copenhagen, Denmark.

Exiqon A/S engages in the development of solutions for ribonucleic acid research and analysis through its Locked Nucleic Acid proprietary technology. Its products and services are used by researchers in academia, biotech, and pharmaceutical companies around the world to make discoveries about the correlation between gene activity and the development of disease. The company was founded by Mikael Ørum, Henrik Ørum and Troels Koch on November 1, 1995 and is headquartered in Copenhagen, Denmark.

Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved.

Sophion Bioscience A/S develops, manufactures and markets instruments and supplies automated patch clamping. It develops throughput patch clamp solutions for functional characterization of living cells. The firm products are used in pharmaceutical and biotech companies around the world. The company was founded in July 2007 and is headquartered in Ballerup, Denmark.